1Stephensen CB, CaseBolt DB, Gangopadhyay NN. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. Virus Res, 1999,60:181 - 189.
2Vabret A, Mouthon F, Mourez T, Gouarin S, Petitjean J, Freymuth F. Direct diagnosis of human respiratory coronaviruses 229E and OC 43 by the polymerase chain reaction.J Virol Methods,2001,97:59-66.
3Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K,Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM,Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. Low-1 - low-11 (at www.nejm.org on March 31,2003).
7Simon J H M, Claassen E, Correa E C, et al. Managing Severe Acute Respiratory Syndrome (SARS) Intellectual Property Rights: The Possible Role of Patent Pooling [ J ]. Bulletin of the World Health Organization,2005,83 (9) :707 - 710.
8Clark J, Piccolo J, Stanton B, et al. Patent Pools: A Solution to the Problem of Access in Biotechnology Patents[ R]. USPTO White Paper, 2000.
9Seide R, Lecointe M and Granovsky A. Patent Pooling in the Biotechnology Industry[ J]. Licensing Journal,2001,27:28 -29.
10Ebersole T J, Guthrie M C and Goldstein J A. Patent Pool and Standard Setting in Diagnostic Genetics[ J]. Nature Biotechnology, 2005a,23(8) :937 -938.
